Nuformix plc (LSE:NFX) — Market Cap & Net Worth
Market Cap & Net Worth: Nuformix plc (NFX)
Nuformix plc (LSE:NFX) has a market capitalization of $49.22K (GBX404.51 Million) as of September 18, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31640 globally and #1211 in its home market, demonstrating a -8.82% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nuformix plc's stock price GBX0.16 by its total outstanding shares 2609749368 (2.61 Billion). Also see how large is Nuformix plc's balance sheet for a full breakdown of the balance sheet.
Nuformix plc Market Cap History: 2015 to 2026
Nuformix plc's market capitalization history from 2015 to 2026. Data shows change from $714.44K to $49.22K (-23.13% CAGR). Also see Nuformix plc (NFX) cash conversion ratio for how efficiently the company converts equity into cash flow.
Nuformix plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nuformix plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Nuformix plc stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.16x
Nuformix plc's market cap is 2.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $666.82K | $15.00K | -$1.84 Million | 44.45x | N/A |
| 2019 | $2.84 Million | $610.00K | -$1.66 Million | 4.66x | N/A |
| 2020 | $857.33K | $535.00K | -$756.38K | 1.60x | N/A |
| 2021 | $341.35K | $195.55K | -$1.25 Million | 1.75x | N/A |
| 2022 | $107.96K | $50.00K | -$1.11 Million | 2.16x | N/A |
Competitor Companies of NFX by Market Capitalization
Companies near Nuformix plc in the global market cap rankings as of September 18, 2026. Review tangible net worth ratio of Nuformix plc to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Nuformix plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Nuformix plc Historical Marketcap From 2015 to 2026
Between 2015 and today, Nuformix plc's market cap moved from $714.44K to $ 49.22K, with a yearly change of -23.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX49.22K | -39.22% |
| 2025 | GBX80.97K | +436.84% |
| 2024 | GBX15.08K | -85.38% |
| 2023 | GBX103.20K | -4.41% |
| 2022 | GBX107.96K | -68.37% |
| 2021 | GBX341.35K | -60.19% |
| 2020 | GBX857.33K | -69.83% |
| 2019 | GBX2.84 Million | +326.19% |
| 2018 | GBX666.82K | -30.00% |
| 2017 | GBX952.59K | -14.29% |
| 2016 | GBX1.11 Million | +55.56% |
| 2015 | GBX714.44K | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Nuformix plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $49.22K USD |
| MoneyControl | $49.22K USD |
| MarketWatch | $49.22K USD |
| marketcap.company | $49.22K USD |
| Reuters | $49.22K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nuformix plc
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis… Read more